Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-03-23 |
Novosanis (Belgium) MDxHealth (Belgium) |
UrNCollect™ |
|
distribution |
Technology - Services - Diagnostic |
Distribution agreement |
2017-03-23 |
Retrophin (USA - CA) |
|
|
nomination |
Rare diseases |
Nomination |
2017-03-23 |
Pierre Fabre Laboratories (France) Setubio (France) |
Nature Open Library program |
|
collaboration |
Technology - Services |
Collaboration agreement |
2017-03-23 |
Erytech Pharma (France) Fox Chase Cancer Center (USA - PA) |
erymethionase program |
homocystinuria |
research |
Rare diseases - Genetic diseases - Metabolic diseases |
Research agreement |
2017-03-22 |
Galapagos (Belgium) AbbVie (USA - IL) |
novel potentiator and combination therapies in cystic fibrosis |
cystic fibrosis |
R&D
development
commercialisation |
Rare diseases - Genetic diseases |
Milestone |
2017-03-22 |
Atlantic Healthcare (UK) |
chairman of the board of directors |
|
resignation |
Inflammatory diseases - Gastrointestinal diseases |
Resignation |
2017-03-22 |
Avrobio (USA - MA) Dr. Stefan Karlsson at Lund University (Sweden) |
investigational gene therapy to treat Gaucher disease |
Gaucher disease |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
2017-03-21 |
Partners test now |
Compound: |
Disease: |
Type of agreement: |
Therapeutic_area:asdsadas |
Plant acquisition |
2017-03-21 |
MDxHealth (Belgium) Lab21 (UK), part of the Novacyt Group (France) |
SelectMDx™ for Prostate Cancer test |
prostate cancer |
distribution |
Cancer - Oncology - Diagnostic |
Distribution agreement |
2017-03-21 |
Argen-X (Belgium - The Netherlands) Broteio Pharma (The Netherlands) |
antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. |
autoimmune haemolytic anaemia (AIHA), antibody mediated rejection (AMR) following organ transplantation. |
development |
Autoimmune diseases |
Development agreement |
2017-03-21 |
Piqur Therapeutics (Switzerland) |
|
|
nomination |
|
Nomination |
2017-03-21 |
X-Chem (USA - MA) Ono Pharmaceutical (Japan) |
small molecules |
|
development
commercialisation |
Cancer - Oncology |
Development agreement |
2017-03-21 |
Pierre Fabre (France) H-Immune (France) |
fully human monoclonal antibody candidates |
|
research
development |
Cancer - Oncology |
R&D agreement |
2017-03-21 |
Stimunity (France) Institut Curie (France) Inserm (France) |
VLP-cGAMP technology |
|
licensing
R&D |
Cancer - Oncology |
Licensing agreement |
2017-03-21 |
Oramed Pharmaceuticals (Israel) |
|
|
nomination |
Metabolic diseases |
Nomination |
2017-03-20 |
Arix Bioscience (UK) the Lead Discovery Center (Germany) Max Planck Innovation (Germany) the University of Leeds (UK) |
antagonists of a novel target for a variety of metabolic indications |
|
|
Cardiovascular diseases - Metabolic diseases |
Development agreement |
2017-03-20 |
Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) |
pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib |
|
development, commercialisation |
Cancer - Oncology - Diagnostic |
Development agreement |
2017-03-20 |
Arena Pharmaceuticals (USA - CA) |
|
|
nomination |
|
Nomination |
2017-03-20 |
Bluebird bio (USA - MA) |
Chief Technology and Manufacturing Officer, Senior Vice President, Corporate Development and Strategy. |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-03-20 |
BMS (USA - NY) CytomX Therapeutics (USA - CA) |
probodies for up to six oncology targets including CTLA-4 |
|
licensing
development |
Cancer - Oncology |
Development agreement |